A phase 0 analysis of ixazomib in patients with glioblastoma
Authors:
- 13 August 2020
- journal article
- research article
- Published by Spandidos Publications in Molecular and Clinical Oncology
- Vol. 13 (5) , 1
Abstract
Improving overall survival in recurrent glioblastoma remains a challenge, and drugs acting by unique mechanisms are urgently required. Ixazomib is an orally‑administered proteasome inhibitor used in combination with lenalidomide and dexamethasone to treat patients with multiple myeloma who have received at least one prior therapy. However, ixazomib's ability to reach brain tumors has not been studied during its development. The aim of the present study (ClinicalTrials.gov, NCT02630030) was to establish and quantify ixazomib's presence in glioblastoma. The present study investigated 3 patients with recurrent glioblastoma after administration of oral ixazomib citrate (MLN 9708) at a fixed 4.0 mg dose within a 3‑hpreoperative window. A total of 2 blood samples were taken from each patient at the time of incision, tumor sampling and closure. Brain tumor samples were collected during tumor resection. These samples were then used to measure the plasma and brain tumor tissue concentration of the biologically‑active form of ixazomib (MLN 2238). Patient 1 had plasma concentrations of ixazomib averaging 26.2, 21.8 and 15.3 ng/ml at incision, tumor sampling and closure, respectively. The brain tumor tissue concentration was 7.88 ng/g. Patient 2 had the same interval and brain tumor tissue measurements of 19.0, 18.0 and 8.93 ng/ml, and 2.03 ng/g. Patient 3 had plasma concentration interval measurements of 25.6, 36.2 and 28.7 ng/ml. Multiple brain tumor tissue samples were taken in patient 3, with an average tissue ixazomib concentration of 3.37 ng/g. Ixazomib was found at plasma concentrations commensurate with its previously established pharmacokinetic profile without clinically relevant drug‑related adverse events. Ixazomib reaches glioblastoma tissues at measurable concentrations at the time of tumor resection, confirming target tissue delivery. This justifies the phase I study of ixazomib in recurrent glioblastoma currently in development.Keywords
This publication has 20 references indexed in Scilit:
- Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform LabellingClinical Pharmacokinetics, 2017
- Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 studyThe Lancet Oncology, 2014
- Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patientsBlood, 2014
- Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myelomaBlood, 2014
- Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human CancerCancer Research, 2010
- Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histologyNeuro-Oncology, 2010
- Activity of bortezomib in glioblastoma.2007
- The nuclear proteasome and the degradation of oxidatively damaged proteinsAmino Acids, 2006
- Proteasome inhibitors: a novel class of potent and effective antitumor agents.1999
- Topographic anatomy and CT correlations in the untreated glioblastoma multiformeJournal of Neurosurgery, 1988